Compare GSAT & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSAT | PTCT |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 5.3B |
| IPO Year | 2006 | 2013 |
| Metric | GSAT | PTCT |
|---|---|---|
| Price | $68.44 | $77.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $52.75 | ★ $73.76 |
| AVG Volume (30 Days) | 1.0M | ★ 2.3M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 8.94 |
| Revenue | $262,202,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $10.89 | $128.32 |
| Revenue Next Year | $10.07 | N/A |
| P/E Ratio | ★ N/A | $8.64 |
| Revenue Growth | 8.54 | ★ 97.54 |
| 52 Week Low | $17.24 | $35.95 |
| 52 Week High | $70.83 | $87.50 |
| Indicator | GSAT | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 71.09 | 54.29 |
| Support Level | $58.02 | $73.03 |
| Resistance Level | $62.68 | $79.03 |
| Average True Range (ATR) | 3.73 | 3.38 |
| MACD | 0.30 | -0.70 |
| Stochastic Oscillator | 85.91 | 29.37 |
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.